GHGlenda Hoffecker

Glenda Hoffecker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Glenda Hoffecker has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterizing Resources and Workforce Needs for Pharmacogenomics Programs Worldwide: Pharmacogenomics Global Research Network Implementation Working Group Landscape Survey

    by Amanda L. Elchynski, James M. Stevenson, Ronald Campbell, Benjamin Q. Duong, Nihal El Rouby, Christina L. Aquilante, Hana Al Alshaykh, Salma A. Bargal, Rebecca Brand, Larisa H. Cavallari, et al.

  • Open Access

    CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

    by Rachael M. Stone, Glenda Hoffecker, April Schultz, Brittney H. Davis, Salma A. Bargal, Amber L. Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J. Rodriguez, Nita Limdi, et al.

    Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles. While CYP2C19 ‐guided DAPT is well‐established for some cardiovascular indications, its use in neurovascular settings has remained limited until recently. This study characterized current implementation strategies for CYP2C19 ‐guided DAPT for neurovascular indications across institutions in the Pharmacogenomics Global Research Network Implementation Working Group. A REDCap survey was distributed to 54 institutions targeting those currently utilizing or planning to implement CYP2C19 testing to guide clopidogrel use for neurovascular indications. The survey collected data on implementation status, workflows, testing logistics, clinical decision support (CDS), and guideline concordance. Fifteen institutions met inclusion criteria; 80% were in the United States and 87% were academic centers. CYP2C19 testing was used for neurovascular indications at 12 sites, most commonly for AIS, intracranial aneurysm repair, and intracranial stenting. Implementation was often built on infrastructure previously established for cardiovascular indications. Most sites used multigene panels, offered testing in both inpatient and outpatient settings, and returned results within 7 days. Eighty percent of sites provided CDS to support application of results. All sites recommended an alternative P2Y12 inhibitor (e.g., ticagrelor) for poor metabolizers, and most did for intermediate metabolizers. CYP2C19 ‐guided antiplatelet therapy for neurovascular indications is expanding, with many implementations leveraging preexisting infrastructure from cardiovascular settings. Broader adoption and outcome‐focused research are needed to optimize the clinical utility of genotype‐guided DAPT in neurovascular care.


  • Open Access

    Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer

    by Arravinth Anantharajah, Raza Chaudhry, Victoria A. Wittner, Mari Angelica S. Cayabyab, Glenda Hoffecker, Xingmei Wang, Laura J. Conway, Ursina R. Teitelbaum, Sony Tuteja

    Pharmacogenetics (PGx) applies knowledge of drug‐gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT‐GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non‐White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge ( β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female ( β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self‐reported health literacy ( β = 2.2, 95% CI [0.9, 3.5], p < 0.001). Participants were less willing to undergo testing if they had health insurance concerns ( β = −3.7, 95% CI [−5.8, −1.7], p < 0.001) or did not complete secondary education ( β = −2.0, 95% CI [−3.5, −0.6], p = 0.006). Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient‐informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research‐engaged and from a single institution, the study population may not be widely generalizable.


  • Open Access

    Patient and provider perspectives on the implementation of DPYD testing in oncology care clinics in an academic health system

    by Victoria Wittner, Jasmine Purcell, Mari Cayabyab, Glenda Hoffecker, Jillian Kalman, Ursina Teitelbaum, Robert Schnoll, Katharine A. Rendle, Sony Tuteja


  • Open Access

    Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial

    by Sony Tuteja, Mari Angelica S. Cayabyab, Glenda Hoffecker, Lisa A. Varughese, Jean de Dieu Ndayishimiye, Victoria A. Wittner, Xingmei Wang, Rachel Hatch, Donna Capozzi, Margaret Harr, et al.

    PURPOSE: To determine the feasibility and effectiveness of implementing pretreatment DPYD/UGT1A1 testing in patients with gastrointestinal cancer and its impact compared with a biobank population. MATERIALS AND METHODS: A prospective, nonrandomized implementation trial of pretreatment DPYD/UGT1A1 testing with preemptive dose reduction was conducted in patients initiating treatment with a fluoropyrimidine (FP, [fluorouracil or capecitabine]) or irinotecan. The primary end point was feasibility, defined as proportion of results available prior to cycle 1 of treatment. Secondarily, occurrence of severe treatment-related adverse events (TRAEs), defined as toxicity resulting in hospitalization or emergency department visit, was compared with a biobank population receiving standard dose chemotherapy. RESULTS: Of the 288 patients prospectively tested, 225 (median age 60.7 years, 54% male, 18% Black, 47% colorectal cancer) received a qualifying chemotherapy. Eight of 11 DPYD variant carriers received an FP and eight of 39 UGT1A1 poor metabolizers received irinotecan. The median test turnaround time was 10 days (IQR, 9-13) with 57.4% of results available before cycle 1. Eleven of 16 (69%) participants with a drug-gene interaction (DGI) had results available before chemotherapy initiation and received pharmacogenetic-recommended dose reductions. Compared with the biobank cohort (n = 229), the prospective DGI group experienced fewer severe TRAEs (38% v 65%, P = .123), treatment discontinuations (31% v 47%, P = .356), and treatment modifications (38% v 76%, P = .028). CONCLUSION: Pretreatment DPYD/UGT1A1 testing and dose reduction was feasible, enabling clinicians to make the appropriate chemotherapy dose reductions, reducing occurrence of adverse outcomes. DPYD/UGT1A1 testing is an important precision oncology approach to optimize patient safety.


  • Open Access

    A call for reporting of tumor‐specific outcomes in studies of DPYD genotyping

    by Jean De Dieu Ndayishimiye, Mari Cayabyab, Glenda Hoffecker, Victoria Wittner, Penn Medicine Biobank, Sony Tuteja

  • Open Access

    Decoding pharmacogenomic test interpretation and application to patient care

    by Roseann S. Donnelly, Larisa H. Cavallari, Jeannine S. McCune, Jennifer Trofe‐Clark, Christine M. Formea, Glenda Hoffecker, Molly M. Csere, Keri C. Anderson, Shubha Bhat, Scott A. Mosley, et al.

    Pharmacogenomics is a growing area of medicine, and pharmacists across clinical practice settings have the opportunity to individualize medication selection and dosing using genetic data. However, many practicing pharmacists may feel ill‐equipped to interpret pharmacogenomic test results because of insufficient education and training. Evidence‐based, updated, and freely available resources such as the Clinical Pharmacogenetics Implementation Consortium guidelines can help pharmacists interpret and apply pharmacogenomic test results to patient care. Although gaps for the application of pharmacogenomic information exist, this commentary aims to demystify the interpretation of pharmacogenomic test results and empower pharmacists to apply genetic data alongside other clinical variables to optimize medication‐related outcomes for their patients. An “ABCD” framework is proposed to guide pharmacists through the steps: (1) Actionability—Are the gene(s) clinically relevant for the patient? (2) Be Mindful of Limitations—What are the caveats with pharmacogenomic test results and reports? (3) Clinical Practice Guidelines—How do you use pharmacogenomic test results to guide clinical decision‐making? and (4) Document and Discuss—How do you educate the patient about their pharmacogenomic test results and document the results for future use? Key concepts are illustrated using a psychiatric patient case example.


  • Establishing a patient‐centered, multidisciplinary pharmacogenomics clinic in an academic health system: Successes, challenges, and future direction

    by Glenda Hoffecker, Mari Cayabyab, Lisa A. Varughese, Stephanie Byers Asher, Archna Bajaj, Sony Tuteja

    Introduction: Pharmacogenomics (PGx) testing uses a patient's deoxyribonucleic acid (DNA) profile to tailor medications with the goal of preventing adverse drug reactions and improving pharmacotherapy outcomes. Despite the availability of evidence‐based guidelines that assist with interpretation of PGx results, PGx testing has not been widely adopted.Objective: To describe how a multidisciplinary PGx clinic was implemented within the University of Pennsylvania Health System (Penn Medicine) including the clinical workflow, challenges to implementation, and future directions.Methods: This project qualified as Quality Improvement by the University of Pennsylvania's Institutional Review Board and adheres to the Standards for Quality Improvement Reporting Excellence (SQUIRE) 2.0 guidelines. Clinic metrics were collected from February 2019 until December 2022. Data collected included patient demographics; the timing of PGx test ordering and appointments; number and frequency of actionable PGx phenotypes; number of current or historical medications impacted by PGx test results; and patient's out‐of‐pocket cost for PGx test.Results: Of the 69 patients included, the majority were female (58%), white (84%), with a mean age of 48 years. The overall time between the dates of the PGx test order and clinic visit was 37 days. The time between the dates of the PGx test order and the PGx test results were generated was 18 days. All patients had at least one actionable PGx phenotype and 74% had three or more. The most frequent actionable phenotypes were found in the cytochrome P450 PC19 (CYPC19) (60%) and CYP2D6 (58%) genes. The percentage of patients that had drug‐gene interactions that affected their current medications and explained historical medication intolerances were 25% and 17%, respectively. Out‐of‐pocket costs were less than $300 for most patients who had a PGx test ordered by the clinic physician.Conclusion: This paper has established a sustainable PGx clinic workflow with dedicated personnel. In the future we intend to increase the availability of our services.


  • Open Access

    An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers

    by Akinyemi Oni‐Orisan, Sony Tuteja, Glenda Hoffecker, D. Max Smith, Matteo Castrichini, Kristine R. Crews, William A. Murphy, Nam H. K. Nguyen, Yimei Huang, Christelle Lteif, et al.

    Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality.


  • Open Access

    Customizing the electronic health record for delivery of pharmacogenetics

    by Glenda Hoffecker, Lisa A. Varughese, Joseph Bleznuck, Jeffrey Landgraf, Collin Wollack, Jessica Chen, Marylyn D. Ritchie, Katherine L. Nathanson, Sony Tuteja